Posted by Michael Wonder on 08 Feb 2023
Nivolumab in combination with fluoropyrimidine- and platinum-based chemotherapy for patients with untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma
8 February 2023 - Nivolumab, when used in combination with fluoropyrimidine-based and platinum-based combination chemotherapy, is recommended as an option for the first-line treatment of adults with unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma whose tumours express PD‑L1 at a level of 1% or more.
It is recommended only if pembrolizumab plus chemotherapy is not suitable and BMS provides nivolumab according to the commercial arrangement.
